<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04056975</url>
  </required_header>
  <id_info>
    <org_study_id>SP071744</org_study_id>
    <nct_id>NCT04056975</nct_id>
  </id_info>
  <brief_title>Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma</brief_title>
  <acronym>A-319</acronym>
  <official_title>A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EVIVE Biotechnology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>EVIVE Biotechnology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Title: A Phase I, Single Centre, Open-label, Dose-escalation Study of A-319 in Patients With&#xD;
      Relapsed or Refractory B-cell Lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol Number: SP071744 Study Stage: Phase I Study Number: 1 site Subject Number: up to 54&#xD;
      patients with Relapsed or Refractory B-cell Lymphoma&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2019</start_date>
  <completion_date type="Anticipated">January 27, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the Incidence and Characteristics of SAE of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Incidence and Characteristics of SAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate the MTD and DLT of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>dose limited toxicity(DLT), maximum tolerance dose(MTD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK(Cmax) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>Peak Plasma Concentration(Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK(AUC) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>Area under the plasma concentration versus time curve(AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK(Tmax) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>time to peak (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK(T1/2) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>half-life time(T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK(CL) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>clearance(CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PK(Vz) of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>volume of distribution(Vz)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the PD of A-319 Treat on Relapsed or Refractory B-cell Lymphoma</measure>
    <time_frame>At the end of Cycle3 (each cycle is 28 days)</time_frame>
    <description>B-cell level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Relapsed or Refractory B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A-319 dosage: 0.05, 0.15, 0.03, 0.06, 0.12, 0.18, 0.24 μg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Anti-CD19m-CD3 Antibody Injection</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years, all genders&#xD;
&#xD;
          -  Patients with definite B-cell Lymphoma, includes FL, MZL, MCL, DLBCL.&#xD;
&#xD;
          -  Patients With Relapsed or Refractory B-cell Lymphoma&#xD;
&#xD;
          -  ECOG ≤ 2&#xD;
&#xD;
          -  Lesions are measurable in 21 days before treatment&#xD;
&#xD;
          -  Normal bone marrow function&#xD;
&#xD;
          -  Normal liver, kidney, lung and heart function&#xD;
&#xD;
          -  the Subjects can sign the ICF and obey the protocol, elsewise, his/her guardian should&#xD;
             sign&#xD;
&#xD;
          -  Life expectancy is at least 3 months&#xD;
&#xD;
        Exclusion Criteria:• Past or present CNS disease&#xD;
&#xD;
          -  Associated with lymphoma by the infiltrates of CNS&#xD;
&#xD;
          -  A history of autoimmune disease with CNS involvement or autoimmune disease&#xD;
&#xD;
          -  Previous history of autoimmune disease or other malignancy&#xD;
&#xD;
          -  A history of deep venous thrombosis or pulmonary embolism&#xD;
&#xD;
          -  Auto-HSCT was performed within 12 weeks prior to initiation of treatment&#xD;
&#xD;
          -  Previous organ transplantation or allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  The Investigator determined that the patients were associated with a disease, medical&#xD;
             condition, or social factor that might affect study results or compliance&#xD;
&#xD;
          -  Immunosuppressant are being used&#xD;
&#xD;
          -  Radiotherapy was given within 6 weeks prior to A-319 treatment&#xD;
&#xD;
          -  Chemotherapy, immunotherapy and targeted therapy were received within 4 weeks before&#xD;
             A-319 treatment&#xD;
&#xD;
          -  Previous CAR-T cell therapy&#xD;
&#xD;
          -  Received anti-lymphoma drugs in the first 4 weeks of A-319 treatment&#xD;
&#xD;
          -  There was no recovery of toxic effects (CTCAE&gt; grade 1 adverse events) at the last&#xD;
             treatment, except hair loss&#xD;
&#xD;
          -  Those who underwent major surgery 28 days before enrollment (excluding lymph node&#xD;
             biopsy);Or plan to operate during the study period&#xD;
&#xD;
          -  Those who had received active/attenuated live vaccine within 28 days prior to&#xD;
             screening&#xD;
&#xD;
          -  For pregnant (positive pregnancy test) and lactating women, those of childbearing age&#xD;
             who signed the informed consent form and did not agree to use contraception for at&#xD;
             least 3 months after the end of the study;Within 7 days prior to the first day of&#xD;
             treatment, women of childbearing age require a positive serum pregnancy test (HCG)&#xD;
&#xD;
          -  Male patients who signed informed consent forms and did not agree to use contraception&#xD;
             for at least 3 months at the end of the study (except surgical sterilization)&#xD;
&#xD;
          -  Known allergy to immunoglobulin or research drugs and their excipients&#xD;
&#xD;
          -  Patients considered unfit to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Song Yuqin, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Jing, Bachelor</last_name>
    <phone>8613524953174</phone>
    <email>yangj@generonbiomed.com</email>
  </overall_contact>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2019</study_first_posted>
  <last_update_submitted>August 13, 2019</last_update_submitted>
  <last_update_submitted_qc>August 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After 20January2022(estimated), for 1years(estimated).</ipd_time_frame>
    <ipd_access_criteria>All.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

